SPOTLIGHT: Product delay dents Sinclair shares

Shares of the UK's Sinclair Pharma slid 13 percent after the company announced that its U.S. partner planned to delay the launch of Decapinol for gum disease in order to explore a new formulation. They hope to launch the new formulation next year. The partner, OraPharma, wants to explore adding a preservative to the product--evidently as a response to a recent J&J recall. Report

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.